Refractory Multiple Myeloma Clinical Trials in Nashville, Tennessee
9 recruitingNashville, Tennessee
Showing 1–9 of 9 trials
Recruiting
Phase 3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Relapsed/Refractory Multiple Myeloma
AstraZeneca508 enrolled116 locationsNCT07391657
Recruiting
Phase 2
MMRC Horizon One: RRMM (MMRC-099)
Refractory Multiple MyelomaRelapse Multiple Myeloma
Multiple Myeloma Research Consortium300 enrolled13 locationsNCT06171685
Recruiting
Phase 1Phase 2
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.166 enrolled10 locationsNCT07116616
Recruiting
Phase 1Phase 2
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Relapsed/Refractory Multiple Myeloma
AstraZeneca182 enrolled36 locationsNCT05850234
Recruiting
Phase 1
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Relapsed/Refractory Multiple Myeloma
Ichnos Sciences SA200 enrolled32 locationsNCT05862012
Recruiting
Phase 1Phase 2
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Refractory Multiple MyelomaRecurrent Multiple Myeloma
Alliance for Clinical Trials in Oncology88 enrolled40 locationsNCT06232044
Recruiting
Phase 1
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company187 enrolled19 locationsNCT06153251
Recruiting
Phase 1
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Caribou Biosciences, Inc.50 enrolled16 locationsNCT05722418
Recruiting
Phase 1Phase 2
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Multiple MyelomaNHLRefractory Non-Hodgkin Lymphoma+4 more
Indapta Therapeutics, INC.128 enrolled12 locationsNCT06119685